HRP960616A2 - Quinoline and quinazoline compounds useful in therapy - Google Patents
Quinoline and quinazoline compounds useful in therapyInfo
- Publication number
- HRP960616A2 HRP960616A2 HR9526546.8A HRP960616A HRP960616A2 HR P960616 A2 HRP960616 A2 HR P960616A2 HR P960616 A HRP960616 A HR P960616A HR P960616 A2 HRP960616 A2 HR P960616A2
- Authority
- HR
- Croatia
- Prior art keywords
- quinoline
- therapy
- compounds useful
- quinazoline compounds
- quinazoline
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9526546.8A GB9526546D0 (en) | 1995-12-23 | 1995-12-23 | Compounds useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP960616A2 true HRP960616A2 (en) | 1998-06-30 |
Family
ID=10786091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR9526546.8A HRP960616A2 (en) | 1995-12-23 | 1996-12-23 | Quinoline and quinazoline compounds useful in therapy |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US6103738A (fr) |
| EP (1) | EP0877734B1 (fr) |
| JP (1) | JP3070958B2 (fr) |
| KR (1) | KR19990076693A (fr) |
| AP (1) | AP715A (fr) |
| AR (1) | AR005166A1 (fr) |
| AT (1) | ATE194598T1 (fr) |
| AU (1) | AU708979B2 (fr) |
| BG (1) | BG102559A (fr) |
| BR (1) | BR9612263A (fr) |
| CA (1) | CA2236814C (fr) |
| CO (1) | CO4480106A1 (fr) |
| CZ (1) | CZ197698A3 (fr) |
| DE (1) | DE69609353T2 (fr) |
| DK (1) | DK0877734T3 (fr) |
| ES (1) | ES2151192T3 (fr) |
| GB (1) | GB9526546D0 (fr) |
| GR (1) | GR3034225T3 (fr) |
| HN (1) | HN1996000082A (fr) |
| HR (1) | HRP960616A2 (fr) |
| HU (1) | HUP9903560A3 (fr) |
| IS (1) | IS4731A (fr) |
| MA (1) | MA26414A1 (fr) |
| NO (1) | NO982913L (fr) |
| NZ (1) | NZ325248A (fr) |
| OA (1) | OA10703A (fr) |
| PL (1) | PL327610A1 (fr) |
| PT (1) | PT877734E (fr) |
| SK (1) | SK81698A3 (fr) |
| TN (1) | TNSN96161A1 (fr) |
| TR (1) | TR199801195T2 (fr) |
| WO (1) | WO1997023462A1 (fr) |
| YU (1) | YU68896A (fr) |
| ZA (1) | ZA9610784B (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| GB9711220D0 (en) * | 1997-05-30 | 1997-07-23 | Isis Innovation | Antiarrhythmic agents |
| GB9711650D0 (en) * | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
| BR0113585A (pt) * | 2000-08-31 | 2003-07-29 | Hoffmann La Roche | Derivados quinazolina como antagonistas adrenérgicos alfa-1 |
| CA2432578C (fr) * | 2001-01-02 | 2008-04-01 | F. Hoffmann-La Roche Ag | Derives quinazolone antagonistes de recepteur alpha 1a/b adrenergique |
| US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
| US6734303B2 (en) | 2001-05-18 | 2004-05-11 | Pfizer Inc. | Process for the production of quinazolines |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| EP2280003B1 (fr) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Procédé pour la préparation de modulateurs de kinases de type récepteur |
| BR0314759A (pt) | 2002-09-26 | 2005-07-26 | Pfizer | Derivados de pirazol |
| PL1615909T3 (pl) | 2003-04-23 | 2009-01-30 | Glaxo Group Ltd | Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych |
| WO2005030131A2 (fr) * | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Composes de bis-quinazoline pour le traitement des infections bacteriennes |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| RS56037B1 (sr) * | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| EP3219705B1 (fr) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques de la forme amorphe de n- [2,4-bis (1,1-diméthyléthyl) -5-hydroxyphényl] -1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20080279909A1 (en) * | 2006-05-12 | 2008-11-13 | Cleek Robert L | Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization |
| US8986713B2 (en) * | 2006-05-12 | 2015-03-24 | W. L. Gore & Associates, Inc. | Medical device capable of being compacted and expanded having anti-thrombin III binding activity |
| US9114194B2 (en) * | 2006-05-12 | 2015-08-25 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having high biological activity following mechanical manipulation |
| US8496953B2 (en) * | 2006-05-12 | 2013-07-30 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having a high degree of biological activity following sterilization |
| US8021677B2 (en) | 2006-05-12 | 2011-09-20 | Gore Enterprise Holdings, Inc. | Immobilized biologically active entities having a high degree of biological activity |
| CN101679308B (zh) * | 2007-03-14 | 2014-05-07 | 埃克塞里艾克西斯公司 | Hedgehog途径抑制剂 |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| BRPI0922010A2 (pt) | 2008-11-14 | 2015-12-15 | Hoffmann La Roche | dervivados de quinazolina como antagonistas receptores de nk3 |
| SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| US8426590B2 (en) * | 2009-03-23 | 2013-04-23 | Cipla Limited | Process for the preparation of doxazosin and salts thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| SMT201700026T1 (it) * | 2009-09-03 | 2017-03-08 | Bristol Myers Squibb Co | Chinazoline come inibitori dei canali degli ioni potassio |
| US8591932B2 (en) | 2009-09-17 | 2013-11-26 | W. L. Gore & Associates, Inc. | Heparin entities and methods of use |
| EP2683420B1 (fr) | 2011-03-11 | 2018-05-23 | W. L. Gore & Associates, Inc. | Améliorations d'entités biologiques immobilisées |
| US20140309184A1 (en) * | 2011-09-21 | 2014-10-16 | University Of South Alabama | Methods and compositions for the treatment of ovarian cancer |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| US9938292B2 (en) | 2014-03-24 | 2018-04-10 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Quinoline derivatives as SMO inhibitors |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| RU2018145364A (ru) | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
| SG11202107614PA (en) * | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656174A (en) * | 1982-07-24 | 1987-04-07 | Pfizer Inc. | Quinoline therapeutic agents |
| GB8506174D0 (en) * | 1985-03-09 | 1985-04-11 | Pfizer Ltd | 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives |
| GB8814458D0 (en) * | 1988-06-17 | 1988-07-20 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
-
1995
- 1995-12-23 NZ NZ325248A patent/NZ325248A/en unknown
- 1995-12-23 GB GBGB9526546.8A patent/GB9526546D0/en active Pending
-
1996
- 1996-12-05 DE DE69609353T patent/DE69609353T2/de not_active Expired - Fee Related
- 1996-12-05 BR BR9612263A patent/BR9612263A/pt not_active Application Discontinuation
- 1996-12-05 TR TR1998/01195T patent/TR199801195T2/xx unknown
- 1996-12-05 ES ES96943954T patent/ES2151192T3/es not_active Expired - Lifetime
- 1996-12-05 US US09/091,370 patent/US6103738A/en not_active Expired - Fee Related
- 1996-12-05 KR KR1019980704806A patent/KR19990076693A/ko not_active Ceased
- 1996-12-05 AU AU13719/97A patent/AU708979B2/en not_active Ceased
- 1996-12-05 SK SK816-98A patent/SK81698A3/sk unknown
- 1996-12-05 CA CA002236814A patent/CA2236814C/fr not_active Expired - Fee Related
- 1996-12-05 PT PT96943954T patent/PT877734E/pt unknown
- 1996-12-05 AT AT96943954T patent/ATE194598T1/de not_active IP Right Cessation
- 1996-12-05 HU HU9903560A patent/HUP9903560A3/hu unknown
- 1996-12-05 CZ CZ981976A patent/CZ197698A3/cs unknown
- 1996-12-05 EP EP96943954A patent/EP0877734B1/fr not_active Expired - Lifetime
- 1996-12-05 WO PCT/EP1996/005609 patent/WO1997023462A1/fr not_active Ceased
- 1996-12-05 JP JP9523272A patent/JP3070958B2/ja not_active Expired - Fee Related
- 1996-12-05 DK DK96943954T patent/DK0877734T3/da active
- 1996-12-05 PL PL96327610A patent/PL327610A1/xx unknown
- 1996-12-12 HN HN1996000082A patent/HN1996000082A/es unknown
- 1996-12-18 MA MA24433A patent/MA26414A1/fr unknown
- 1996-12-18 TN TNTNSN96161A patent/TNSN96161A1/fr unknown
- 1996-12-19 AP APAP/P/1996/000900A patent/AP715A/en active
- 1996-12-20 AR ARP960105804A patent/AR005166A1/es unknown
- 1996-12-20 ZA ZA9610784A patent/ZA9610784B/xx unknown
- 1996-12-20 CO CO96066994A patent/CO4480106A1/es unknown
- 1996-12-20 YU YU68896A patent/YU68896A/sh unknown
- 1996-12-23 HR HR9526546.8A patent/HRP960616A2/xx not_active Application Discontinuation
-
1998
- 1998-04-29 IS IS4731A patent/IS4731A/is unknown
- 1998-06-18 BG BG102559A patent/BG102559A/xx unknown
- 1998-06-22 NO NO982913A patent/NO982913L/no not_active Application Discontinuation
- 1998-06-23 OA OA9800092A patent/OA10703A/en unknown
-
2000
- 2000-08-17 GR GR20000401910T patent/GR3034225T3/el not_active IP Right Cessation
-
2001
- 2001-03-19 US US09/812,083 patent/US6642242B2/en not_active Expired - Fee Related
-
2003
- 2003-06-04 US US10/455,546 patent/US6750214B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP9600900A0 (en) | Quinoline and quinazoline compounds useful in therapy | |
| ZA98166B (en) | Quinoline and quinazoline compounds useful in therapy | |
| GB2298422B (en) | Compounds and their use | |
| ZA964334B (en) | Metallocene preparation and use | |
| IL123600A0 (en) | 2(1H)-Quinolone derivatives their preparation and their use in therapy | |
| EP0851759A4 (fr) | Composes et procedes associes | |
| AU1886197A (en) | Quinolones and their therapeutic use | |
| GB2282671B (en) | Diffusing and depixelating means | |
| HU9602956D0 (en) | Porphocyanine and cnc-expanded porphyrins | |
| ZA985253B (en) | Quinolines and their therapeutic use | |
| EP0836617A4 (fr) | Parevines et tachytegrines | |
| ZA983740B (en) | Novel amidine derivatives and their use in therapy | |
| AU2512495A (en) | Therapeutic phenoxyalkylazoles and phenoxyalkylazines | |
| EP0799225A4 (fr) | Composes et procedes associes | |
| GB9523066D0 (en) | Compounds and their therapeutic use | |
| IL115853A0 (en) | Aryloxycycloalkenyl and aryloxyiminocyclo-alkenylhydroxyureas | |
| ZA9710000B (en) | Quinolines and their therapeutic use | |
| GB9714298D0 (en) | Quinolines and their therapeutic use | |
| GB9611898D0 (en) | Quinolones and their therapeutic use | |
| PH30681A (en) | Imidazotriazolo quinazoline compounds and their use | |
| GB9702933D0 (en) | Quinolones and their therapeutic use | |
| IL128220A0 (en) | Quinoline derivatives and uses thereof | |
| GB9609521D0 (en) | Substances and their therapeutic use | |
| GB9621314D0 (en) | Substances and their therapeutic use | |
| ZA967769B (en) | 2(1H)-quinolone derivatives their preparation and their use in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| A1OB | Publication of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 19991223 Year of fee payment: 4 |
|
| ODBC | Application rejected |